The MitraClip® EXPAND Study of the Next Generation of MitraClip® Devices
Launched by ABBOTT MEDICAL DEVICES · Apr 11, 2018
Trial Information
Current as of June 18, 2025
Completed
Keywords
ClinConnect Summary
The data collected in this study will be used to evaluate device outcomes and characterize trends in patient selection for MitraClip therapy in contemporary real-world use. Moreover, the data will be assessed to identify patient or mitral valve anatomical characteristics that may be most appropriate for these next generation devices.
The MitraClip EXPAND Study will be conducted on commercial MitraClip NTR System and MitraClip XTR System that have received CE Mark and/or FDA approval as required.
Up to 1,000 subjects at a maximum of 60 sites in Europe and the US were initially planned to e...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Subjects who give consent for their participation
- • 2. Subjects scheduled to receive the MitraClip per the current approved indications for use
- • 3. Subjects with Symptomatic MR (≥3+)
- Exclusion Criteria:
- • 1. Subjects participating in another clinical study that may impact the follow-up or results of this study
About Abbott Medical Devices
Abbott Medical Devices is a leading global healthcare company dedicated to advancing medical technology through innovative research and development. With a robust portfolio of diagnostic, therapeutic, and monitoring solutions, Abbott is committed to improving patient outcomes and enhancing the quality of care across various medical fields. The company places a strong emphasis on clinical trials to validate the safety and efficacy of its products, ensuring compliance with regulatory standards and fostering collaboration with healthcare professionals. By leveraging cutting-edge science and technology, Abbott Medical Devices aims to address pressing health challenges and deliver transformative solutions that empower patients and healthcare providers alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Aurora, Colorado, United States
Charlotte, North Carolina, United States
Minneapolis, Minnesota, United States
Barcelona, , Spain
Murray, Utah, United States
London, , United Kingdom
Birmingham, Alabama, United States
Eindhoven, , Netherlands
New York, New York, United States
Utrecht, , Netherlands
Milan, , Italy
Sacramento, California, United States
Ulm, , Germany
Jerusalem, , Israel
Barcelona, , Spain
Berlin, , Germany
Nieuwegein, , Netherlands
Aarau, , Switzerland
Bad Nauheim, , Germany
Heidelberg, , Germany
La Jolla, California, United States
Dortmund, , Germany
Osnabrück, , Germany
Charlottesville, Virginia, United States
Bernau, , Germany
Göttingen, , Germany
Leipzig, Saxony, Germany
Düsseldorf, , Germany
Magdeburg, , Germany
Phoenix, Arizona, United States
West Palm Beach, Florida, United States
Chicago, Illinois, United States
Kansas City, Kansas, United States
Kansas City, Missouri, United States
Morristown, New Jersey, United States
New York, New York, United States
New York, New York, United States
Cincinnati, Ohio, United States
Nashville, Tennessee, United States
Norfolk, Virginia, United States
Seattle, Washington, United States
München, Bavaria, Germany
Mainz, Rhinela, Germany
Gießen, , Germany
Hamburg, , Germany
Karlsburg, , Germany
Köln, , Germany
München, , Germany
Jerusalem, , Israel
Milano, Lombard, Italy
Milano, Lombard, Italy
Milano, Lombard, Italy
Catania, Sicilia, Italy
Madrid, , Spain
Málaga, , Spain
Bern, , Switzerland
Zürich, , Switzerland
Patients applied
Trial Officials
Dr. Saibal Kar, MD
Principal Investigator
Cedars Sinai, Los Angeles CA
Prof. Francesco Maisano, MD
Principal Investigator
University Hospital, Zürich
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials